Antibodies are important therapeutic agents for cancer. Recently, it has become clear that
antibodies possess several clinically relevant mechanisms of action. Many clinically useful
antibodies can manipulate tumour-related signalling. In addition, antibodies exhibit various
immunomodulatory properties and, by directly activating or inhibiting molecules of the
immune system, antibodies can promote the induction of antitumour immune responses.
These immunomodulatory properties can form the basis for new cancer treatment strategies.